Epidermolysis Bullosa - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 72 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epidermolysis Bullosa - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Epidermolysis Bullosa - Pipeline Review, H2 2015', provides an overview of the Epidermolysis Bullosa's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Epidermolysis Bullosa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epidermolysis Bullosa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Epidermolysis Bullosa Overview 8
Therapeutics Development 9
Pipeline Products for Epidermolysis Bullosa - Overview 9
Pipeline Products for Epidermolysis Bullosa - Comparative Analysis 10
Epidermolysis Bullosa - Therapeutics under Development by Companies 11
Epidermolysis Bullosa - Therapeutics under Investigation by Universities/Institutes 12
Epidermolysis Bullosa - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Epidermolysis Bullosa - Products under Development by Companies 16
Epidermolysis Bullosa - Products under Investigation by Universities/Institutes 17
Epidermolysis Bullosa - Companies Involved in Therapeutics Development 18
Birken AG 18
Fibrocell Science, Inc. 19
GlaxoSmithKline Plc 20
InMed Pharmaceuticals Inc. 21
Karus Therapeutics Limited 22
RegeneRx Biopharmaceuticals, Inc. 23
Scioderm, Inc. 24
Shire Plc 25
Stratatech Corporation 26
TWi Pharmaceuticals, Inc. 27
Epidermolysis Bullosa - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
allantoin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antisense Oligonucleotides 1 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antisense Oligonucleotides 2 to Inhibit Keratin for Epidermolysis Bullosa Simplex - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cell Therapy for Dermatology and Immunology - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
diacerein - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Gene Therapy for Epidermolysis Bullosa - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Gene Therapy for Epidermolysis Bullosa - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Gene Therapy to Activate Collagen Type VII for Recessive Dystrophic Epidermolysis Bullosa - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GMHDFCOL-7 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
INM-750 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
KA-1463 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
OleogelS-10 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
RGN-137 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
SHP-608 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Epidermolysis Bullosa - Recent Pipeline Updates 55
Epidermolysis Bullosa - Dormant Projects 62
Epidermolysis Bullosa - Discontinued Products 63
Epidermolysis Bullosa - Product Development Milestones 64
Featured News & Press Releases 64
Nov 04, 2015: InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa 64
Oct 08, 2015: Fibrocell and Intrexon Announce Poster Presentation on FCX-007 for the Treatment of RDEB at American Society of Human Genetics Annual Meeting 64
Sep 25, 2015: Fibrocell and Intrexon Provide Regulatory Update for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa 65
Sep 02, 2015: InMed Commences Development of Proprietary Drug Delivery System 66
Aug 06, 2015: InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis bullosa simplex 66
Jul 22, 2015: RegeneRx Receives Notice of Acceptance for Australian Patent for Key TB4 Peptide Fragment 66
Jul 20, 2015: Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa 67
Jul 14, 2015: Scioderm to Submit Rolling NDA to U.S. FDA for Zorblisa 67
Jun 08, 2015: Fibrocell and Intrexon Announce Positive in vitro Pre-Clinical Data for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) at European Society of Human Genetics 68
May 12, 2015: Fibrocell Receives Rare Pediatric Disease Designation From FDA for FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables

Number of Products under Development for Epidermolysis Bullosa, H2 2015 9
Number of Products under Development for Epidermolysis Bullosa - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Number of Products under Investigation by Universities/Institutes, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 13
Comparative Analysis by Clinical Stage Development, H2 2015 14
Comparative Analysis by Early Stage Development, H2 2015 15
Products under Development by Companies, H2 2015 16
Products under Investigation by Universities/Institutes, H2 2015 17
Epidermolysis Bullosa - Pipeline by Birken AG, H2 2015 18
Epidermolysis Bullosa - Pipeline by Fibrocell Science, Inc., H2 2015 19
Epidermolysis Bullosa - Pipeline by GlaxoSmithKline Plc, H2 2015 20
Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc., H2 2015 21
Epidermolysis Bullosa - Pipeline by Karus Therapeutics Limited, H2 2015 22
Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015 23
Epidermolysis Bullosa - Pipeline by Scioderm, Inc., H2 2015 24
Epidermolysis Bullosa - Pipeline by Shire Plc, H2 2015 25
Epidermolysis Bullosa - Pipeline by Stratatech Corporation, H2 2015 26
Epidermolysis Bullosa - Pipeline by TWi Pharmaceuticals, Inc., H2 2015 27
Assessment by Monotherapy Products, H2 2015 28
Number of Products by Stage and Target, H2 2015 30
Number of Products by Stage and Mechanism of Action, H2 2015 32
Number of Products by Stage and Route of Administration, H2 2015 34
Number of Products by Stage and Molecule Type, H2 2015 36
Epidermolysis Bullosa Therapeutics - Recent Pipeline Updates, H2 2015 55
Epidermolysis Bullosa - Dormant Projects, H2 2015 62
Epidermolysis Bullosa - Discontinued Products, H2 2015 63